In the PyMT spontaneous tumor model used in our study, the anti-CD115 mAb by itself could efficiently reduce tumor growth, suggesting that targeting the receptor might have a superior therapeutic effect than blocking CSF-1. This evidence concerns the gene CSF1 and neoplasm.